Publications

At AIDA Oncology, we translate complex tumor biology into clinically validated drug response predictors. Our work focuses on transcriptome-based precision oncology across multiple cancer types, with a particular emphasis on breast cancer.

Epirubicin & Doxorubicin

29-05-2024 | 2024 ASCO Annual Meeting I | Abstract

Predicting epirubicin response in Danish patients with breast cancer.

Buhl, I. K., Nart, J., Papadovasilakis, Z., Sørensen, S., Jensen, P. B., Ejlertsen, B., ... & Tsamardinos, I.

26-05-2019 | 2019 ASCO Annual Meeting I | Abstract

Doxorubicin response prediction in neoadjuvant breast cancer therapy.

Rasmussen, Anna & Christensen, Ib & Knudsen, Steen & Jensen, Peter.

11-08-2018 | Breast Cancer Research and Treatment | Article

Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort: a retrospective-prospective blinded study.

Buhl, A.S.K., Christensen, T.D., Christensen, I.J. et al.

30-05-2017 | 2017 ASCO Annual Meeting I | Abstract

Retrospective-prospective blinded evaluation predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort.

Rasmussen, Anna & Christensen, Troels & Christensen, Ib & Nelausen, Knud & Balslev, Eva & Knoop, Ann & Brix, Eva & Svensson, Else & Glavicic, Vesna & Luczak, Adam & Langkjer, Sven & Linnet, Soeren & Jakobsen, Erik & Bogovic, Jurij & Ejlertsen, Bent & Rasmussen, Annie & Hansen, Anker & Knudsen, Steen & Nielsen, Dorte & Jensen, Peter.

Breast Cancer

20-04-2019 | Pharmacogenomics | Publication

A drug response predictor to guide treatment for breast cancer.

Buhl, I. K., Jensen, P. B., Kappel Buhl, A. S., & Knudsen, S.